A well-known complication of factor VIII replacement therapy in patients with hemophilia A is the development of inhibitory antibodies. Several studies have demonstrated the presence of a binding site for factor VIII inhibitors in the A3 domain. Six different human monoclonal single-chain variable domain antibody fragments (scFv) directed toward the A3-C1 domains of factor VIII have been isolat...

Blood coagulation factors V and VIII each serve cofactor functions with different vitamin K-dependent serine proteases of the coagulation cascade. Physical, physiologic, and kinetic data suggest analogous structures and functions for these two proteins. Proteolytically activated factor V (factor Va) is required for the efficient production of thrombin from prothrombin by factor Xa. Similarly, a...

The gene for the coagulation protein factor VIII contains several common restriction fragment length polymorphisms which can be used to analyse the pattern of inheritance of factor VIII alleles within families. This can be exploited to identify carriers of haemophilia, an X-linked inherited disorder characterised by deficiency of factor VIII. In this study the polymerase chain reaction was used...

A circulating anticoagulant against factor VIII activity was demonstrated in the plasma of a boy from a family with both factor VIII deficiency and prolonged bleeding time. However, the factor VIII-related antigen, ristocetin-induced platelet aggregation activity, platelet retention in glass bead columns, platelet aggregation with adenosine 5'-diphosphate, collagen and epinephrine, and clot ret...

B,, E. E. CLIFFTON, A. GIROLAMI AND D. AG05TIN0 E LLAGIC ACID has beemi shown to cause a hypercoagulable state in several amiimiial species, presumably by activation of Hageman factor ( factor) XII).”2 In the course of experiments with this compound in dogs, rabbits, and cats, a decrease in oozing from venipuncture sites and raw surfaces was noted.2 A significant decrease in bleeding from the a...

Normal human plasma contains a complex of two proteins that are important in hemostasis and coagulation. The factor VIII procoagulant protein (antihemophilic factor) and the factor VIII-related protein (von Willebrand factor) are under separate genetic control, have distinct biochemical properties, and have unique and essential physiologic properties. While the nature of their interaction and t...

a group of iranian patients suffering from factor viii deficiency (hemophilia a) and treated with contaminated coagulation factor (imported), became seropositive as determined by elisa method. sixty of these individuals, which were available, were studied for abo distribution. the b blood group in anti hiv pos. individuals (13.33%) shows a significant decrease in comparison with the total (1504...

Clotting factor V has a dual function in coagulation: after activation, procoagulant factor V stimulates the formation of thrombin, whereas anticoagulant factor V acts as a cofactor for activated protein C (APC) in the degradation of factor VIII/VIIIa, thereby reducing thrombin formation. In the present study, we evaluated whether plasma factor V levels, either decreased or increased, are assoc...